FEMY insider transaction filings
FEMASYS INC — 48 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-11. Screen FEMY transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 10 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 5 legs across 5 filings by 5 insiders — 41,875 shares, $134,000 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 15.
- Largest priced transaction: purchase of 15,625 shares @ $3.20 ($50,000) by Elefant Dov, filed 2026-08-11.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Elefant Dov — Chief Financial Officer | 1 | 1 leg · 15,625 sh · $50,000 | — | 2 |
| Lee-Sepsick Kathy — Chief Executive Officer, Director | 1 | 1 leg · 15,625 sh · $50,000 | — | 2 |
| Canning John Charles — Chief Operating Officer | 1 | 1 leg · 4,375 sh · $14,000 | — | 2 |
| Mifek Jeffrey Gerald — Chief Clinical-Medical Affairs | 2 | 1 leg · 3,125 sh · $10,000 | — | 3 |
| Sipos Jeremy Alexander — Chief Technology Officer | 1 | 1 leg · 3,125 sh · $10,000 | — | 2 |
| Eichenbaum Kenneth D. — Director | 1 | — | — | 1 |
| Larsen Charles — Director | 1 | — | — | 1 |
| Milnes Alistair — Director | 1 | — | — | 1 |
| Uzialko Edward R — Director | 1 | — | — | 1 |
Recent Form 4 filings — FEMASYS INC
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-11 | 4 | Eichenbaum Kenneth D. — Director | Grant/award (A): 880 (derivative) @ $0 | EDGAR |
| 2026-08-11 | 4 | Uzialko Edward R — Director | Grant/award (A): 880 (derivative) @ $0 | EDGAR |
| 2026-08-11 | 4 | Milnes Alistair — Director | Grant/award (A): 880 (derivative) @ $0 | EDGAR |
| 2026-08-11 | 4 | Larsen Charles — Director | Grant/award (A): 880 (derivative) @ $0 | EDGAR |
| 2026-08-11 | 4 | Mifek Jeffrey Gerald — Chief Clinical-Medical Affairs | Purchase (P): 3,125 @ $3.20 · Grant/award (A): 3,125 (derivative) · Grant/award (A): 3,125 (derivative) | EDGAR |
| 2026-08-11 | 4 | Mifek Jeffrey Gerald — Chief Clinical-Medical Affairs | Grant/award (A): 6,250 (derivative) @ $0 | EDGAR |
| 2026-08-11 | 4 | Sipos Jeremy Alexander — Chief Technology Officer | Purchase (P): 3,125 @ $3.20 · Grant/award (A): 3,125 (derivative) · Grant/award (A): 3,125 (derivative) | EDGAR |
| 2026-08-11 | 4 | Canning John Charles — Chief Operating Officer | Purchase (P): 4,375 @ $3.20 · Grant/award (A): 4,375 (derivative) · Grant/award (A): 4,375 (derivative) | EDGAR |
| 2026-08-11 | 4 | Elefant Dov — Chief Financial Officer | Purchase (P): 15,625 @ $3.20 · Grant/award (A): 15,625 (derivative) · Grant/award (A): 15,625 (derivative) | EDGAR |
| 2026-08-11 | 4 | Lee-Sepsick Kathy — Chief Executive Officer, Director | Purchase (P): 15,625 @ $3.20 · Grant/award (A): 15,625 (derivative) · Grant/award (A): 15,625 (derivative) | EDGAR |
| 2026-04-01 | 4 | Canning John Charles — Chief Operating Officer | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2026-03-27 | 4 | Eichenbaum Kenneth D. — Director | Grant/award (A): 102,366 (derivative) | EDGAR |
| 2026-03-27 | 4 | Lee-Sepsick Kathy — Chief Executive Officer, Director | Grant/award (A): 68,244 (derivative) | EDGAR |
| 2026-03-27 | 4 | Larsen Charles — Director | Grant/award (A): 34,122 (derivative) | EDGAR |
| 2026-03-27 | 4 | Elefant Dov — Chief Financial Officer | Grant/award (A): 34,122 (derivative) | EDGAR |
| 2026-03-20 | 4 | Eichenbaum Kenneth D. — Director | Grant/award (A): 35,200 (derivative) @ $0 | EDGAR |
| 2026-03-18 | 4 | Silverman Joshua — Director | Holdings only — no transactions reported | EDGAR |
| 2026-03-18 | 4 | PharmaCyte Biotech, Inc. — 10% owner | Holdings only — no transactions reported | EDGAR |
| 2026-02-20 | 4 | Lee-Sepsick Kathy — Chief Executive Officer, Director | Grant/award (A): 447,000 (derivative) @ $0 · Grant/award (A): 282,000 (derivative) @ $0 | EDGAR |
| 2026-02-20 | 4 | Elefant Dov — Chief Financial Officer | Grant/award (A): 173,000 (derivative) @ $0 · Grant/award (A): 169,000 (derivative) @ $0 | EDGAR |
| 2026-02-17 | 4 | Sipos Jeremy Alexander — Chief Technology Officer | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2025-11-19 | 4 | Lee-Sepsick Kathy — Chief Executive Officer, Director | Code (I) · Code (I): 68,244 (derivative) · Code (I): 68,244 (derivative) · Code (I): 68,244 (derivative) | EDGAR |
| 2025-11-12 | 4 | Larsen Charles — Director | Code (I) · Code (I): 34,122 (derivative) · Code (I): 34,122 (derivative) · Code (I): 34,122 (derivative) | EDGAR |
| 2025-11-12 | 4 | Elefant Dov — Chief Financial Officer | Code (I) · Code (I): 34,122 (derivative) · Code (I): 34,122 (derivative) · Code (I): 34,122 (derivative) | EDGAR |
| 2025-08-28 | 4 | Lee-Sepsick Kathy — Chief Executive Officer, Director | Code (I): 48,535 · Code (I): 48,535 (derivative) | EDGAR |
| 2025-08-28 | 4 | Elefant Dov — Chief Financial Officer | Code (I): 38,828 · Code (I): 38,828 (derivative) | EDGAR |
| 2025-07-01 | 4 | Nicholas Kelley Stinson — Chief Commercial Officer | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | Uzialko Edward R — Director | Grant/award (A): 17,600 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | Milnes Alistair — Director | Grant/award (A): 17,600 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | Larsen Charles — Director | Grant/award (A): 17,600 (derivative) @ $0 | EDGAR |
| 2025-06-27 | 4 | Silverman Joshua — Director | Grant/award (A): 17,600 (derivative) @ $0 | EDGAR |
| 2025-06-04 | 4 | Larsen Charles — Director | Code (I): 24,510 @ $1.02 | EDGAR |
| 2025-06-04 | 4 | Currie Daniel Scott — Chief Operating Officer | Code (I): 19,608 @ $1.02 | EDGAR |
| 2025-06-04 | 4 | Lee-Sepsick Kathy — Chief Executive Officer, Director | Code (I): 34,314 @ $1.02 | EDGAR |
| 2025-06-04 | 4 | Elefant Dov — Chief Financial Officer | Code (I): 19,608 @ $1.02 | EDGAR |
| 2025-01-30 | 4 | Currie Daniel Scott — Chief Operating Officer | Grant/award (A): 29,184 (derivative) @ $0 · Grant/award (A): 59,313 (derivative) @ $0 · Grant/award (A): 140,700 (derivative) @ $0 | EDGAR |
| 2025-01-30 | 4 | Thomas Christine E — Chief Reg & Clinical Officer | Grant/award (A): 55,090 (derivative) @ $0 · Grant/award (A): 28,682 (derivative) @ $0 · Grant/award (A): 23,600 (derivative) @ $0 | EDGAR |
| 2025-01-30 | 4 | Lee-Sepsick Kathy — Chief Executive Officer, Director | Grant/award (A): 59,849 (derivative) @ $0 · Grant/award (A): 120,353 (derivative) @ $0 · Grant/award (A): 262,700 (derivative) @ $0 | EDGAR |
| 2025-01-30 | 4 | Elefant Dov — Chief Financial Officer | Grant/award (A): 72,045 (derivative) @ $0 · Grant/award (A): 114,300 (derivative) @ $0 | EDGAR |
| 2024-07-15 | 4 | Silverman Joshua — Director | Grant/award (A): 17,600 (derivative) @ $0 | EDGAR |
| 2024-07-15 | 4 | Larsen Charles — Director | Grant/award (A): 17,600 (derivative) @ $0 | EDGAR |
| 2024-07-15 | 4 | Milnes Alistair — Director | Grant/award (A): 17,600 (derivative) @ $0 | EDGAR |
| 2024-07-15 | 4 | Uzialko Edward R — Director | Grant/award (A): 17,600 (derivative) @ $0 | EDGAR |
| 2024-02-13 | 4 | Spector Richard D. — Chief Commercial Officer | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2024-02-02 | 4 | Currie Daniel Scott — Chief Operating Officer | Grant/award (A): 61,900 (derivative) @ $0 | EDGAR |
| 2024-02-02 | 4 | Elefant Dov — Chief Financial Officer | Grant/award (A): 84,000 (derivative) @ $0 | EDGAR |
| 2024-02-02 | 4 | Thomas Christine E — SVP, Regulatory & Clinical | Grant/award (A): 32,600 (derivative) @ $0 | EDGAR |
| 2024-02-02 | 4 | Lee-Sepsick Kathy — Chief Executive Officer, Director | Grant/award (A): 204,900 (derivative) @ $0 | EDGAR |
Recent 8-K events — FEMASYS INC
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-11 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-24 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-24 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-06-05 | 8-K | 3.03 — Material Modification to Rights of Security Holders 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-04 | 8-K | 7.01 — Regulation FD Disclosure | EDGAR |
| 2026-05-13 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-08 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-29 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-04-01 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=FEMY returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →